Of note, FcγR polymorphisms have been characterized in patient tumor samples from clinical trials using conatumumab for the treatment of soft tissue sarcoma [130], colorectal cancer [122,132], and NSCLC [125] and tigatuzumab for the treatment of NSCLC [129] in an effort to determine if FcγR polymorphisms segregated with outcomes. This evidence concerns the gene FCGR2A and colorectal cancer.